 |
| Prof Barritault with Al Tafa’ol Trading Establishment deputy general manager Mohamed Aslam and other officials |
The product, CACIPLIQ20, is a sterile liquid wound application applied to acute or chronic wounds. “It promotes a healing environment by providing a scaffold to healing tissue, protecting the elements in the extra cellular matrix and allowing tissue regeneration to occur.
The seminar was organised by Al Tafa’ol Trading Establishment, a Doha-based distributor of pharmaceutical, cosmetic, and other healthcare products in Qatar.
Prof Barritault from Paris University spoke on the new treatment and presented the results obtained on many patients in Europe and Saudi Arabia from the last six months.
“CACIPLIQ20 can be effective in more than 95% of patients, assuming that diabetes is controlled and that patients do not walk on their ulcer,” he explained.
The technology comes from research that Barritault led when he was chairman at Paris-Est University and headed a research laboratory under the French National Research Centre (CNRS) for the last two decades of his academic career.
His focus was to understand the reasons and biological mechanisms involved in replacing dead cells with identical new cells each time a single cell dies and the reason it does not occur when many cells die but leaves traces known as scars or fibrosis.
Barritault found that a key element that governed this biological law was located in the cellular environment. It is a large molecule called heparin sulfate which organises a scaffold around the cells, he explained.
Given that heparin sulphate gets destroyed in wounds, Barritault engineered a molecule that would be able to replace the destroyed heparin sulfate so that it could restore the scaffold.
Barritault then successfully demonstrated that this molecule when introduced at the site of a lesion after an injury was able to reinitiate the tissue as was before the injury.
This demonstration was given in more than 20 animal models and nine species.
Over 80 international publications in noted scientific journals carried this research that lasted 16 years.
The conclusion was that mammals can regenerate if properly treated by the product Barritault called RGTA for ReGeneraTing Agent.
The technology is named Matrix Therapy in regenerative medicine and is a new branch just as stem cells therapy.
Barritault floated the company OTR3 in Paris and went through all the process of drug safety and efficacy issues to obtain marketing authorisation for his first product - CACIPLIQ20 - adapted for skin wounds.
Al Tafa’ol Trading Establishment deputy general manager Mohamed Aslam welcomed the gathering.
